Notice of Request for Public Comments on a Draft Recommendation To Update the HRSA-Supported Women's Preventive Services Guideline Relating to Screening for Urinary Incontinence, 67318-67319 [2023-21514]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
67318
Federal Register / Vol. 88, No. 188 / Friday, September 29, 2023 / Notices
Court of Federal Claims No: 23–1326V
54. Silvia Aguayo, Lancaster, California,
Court of Federal Claims No: 23–1327V
55. Katie B. Tate, Los Angeles, California,
Court of Federal Claims No: 23–1342V
56. Savana Torres, Los Angeles, California,
Court of Federal Claims No: 23–1343V
57. Linda Orbanac, Sayre, Pennsylvania,
Court of Federal Claims No: 23–1344V
58. Angela Battles, White, Georgia, Court of
Federal Claims No: 23–1345V
59. Mark E. Hanson, Minneapolis, Minnesota,
Court of Federal Claims No: 23–1346V
60. Beata Brozek, Evanston, Illinois, Court of
Federal Claims No: 23–1347V
61. Melissa Thomas on behalf of M. T.,
Wilmington, North Carolina, Court of
Federal Claims No: 23–1351V
62. Danyel Nelson, Warwick, Rhode Island,
Court of Federal Claims No: 23–1352V
63. John Schouest, Thibodaux, Louisiana,
Court of Federal Claims No: 23–1353V
64. Nicole Sicuro-Leipski on behalf of G. L.,
Kenosha, Wisconsin, Court of Federal
Claims No: 23–1356V
65. Shalonda Goolsby, Dresher,
Pennsylvania, Court of Federal Claims
No: 23–1357V
66. Alice McCarthy, Renton, Washington,
Court of Federal Claims No: 23–1360V
67. Yesid Hernandez, Naples, Florida, Court
of Federal Claims No: 23–1364V
68. Leah Keller, Washington, District of
Columbia, Court of Federal Claims No:
23–1367V
69. Bethel Stevens, Waimea, Hawaii, Court of
Federal Claims No: 23–1369V
70. Dolores Jefferson, Fairburn, Georgia,
Court of Federal Claims No: 23–1370V
71. Dawn Ferris-Murray, Mount Laurel, New
Jersey, Court of Federal Claims No: 23–
1380V
72. Jeremy Allred, Minneapolis, Minnesota,
Court of Federal Claims No: 23–1385V
73. Mary Louise Spann, Nashville,
Tennessee, Court of Federal Claims No:
23–1395V
74. Vincent Russell, West Chester,
Pennsylvania, Court of Federal Claims
No: 23–1397V
75. Larry Cunningham, Aurora, Colorado,
Court of Federal Claims No: 23–1404V
76. Chinyere Jumbo, Hoover, Alabama, Court
of Federal Claims No: 23–1419V
77. Chinyere Jumbo, Hoover, Alabama, Court
of Federal Claims No: 23–1421V
78. Leora Chasen, Binghamton, New York,
Court of Federal Claims No: 23–1423V
79. Steven Hofmaster, Camas, Washington,
Court of Federal Claims No: 23–1430V
80. Aislynn Hayes, Murfreesboro, Tennessee,
Court of Federal Claims No: 23–1448V
81. Bobby Rossette, Boston, Massachusetts,
Court of Federal Claims No: 23–1477V
82. Maria Bettinger, Houston, Texas, Court of
Federal Claims No: 23–1478V
83. Candy Guzman-Guizar, Alhambra,
California, Court of Federal Claims No:
23–1484V
84. Brian Andrew Vergara, Phoenix, Arizona,
Court of Federal Claims No: 23–1486V
85. Yoshua Rozen, Boston, Massachusetts,
Court of Federal Claims No: 23–1487V
86. Kristen Edwards Dempsey, Honolulu,
Hawaii, Court of Federal Claims No: 23–
1493V
VerDate Sep<11>2014
21:46 Sep 28, 2023
Jkt 259001
87. Andrea Mae Warren, Honolulu, Hawaii,
Court of Federal Claims No: 23–1494V
88. Gina Lewis, Sterling, Kansas, Court of
Federal Claims No: 23–1495V
89. Ollie Phillips, Woodridge, Illinois, Court
of Federal Claims No: 23–1496V
90. Elizabeth Herman, West Chester,
Pennsylvania, Court of Federal Claims
No: 23–1497V
91. John Bovard, Boston, Massachusetts,
Court of Federal Claims No: 23–1498V
92. Kandi Shafer, Woodridge, Illinois, Court
of Federal Claims No: 23–1499V
93. John Yankey, Canby, Oregon, Court of
Federal Claims No: 23–1500V
94. Tynh Maejlauk, Chandler, Arizona, Court
of Federal Claims No: 23–1501V
95. Linda Shaw, DeLand, Florida, Court of
Federal Claims No: 23–1502V
96. Lashay Cameron on behalf of N. C., Jr.,
Deceased, Aventura, Florida, Court of
Federal Claims No: 23–1505V
97. Rebecca Furdell, Cape Coral, Florida,
Court of Federal Claims No: 23–1506V
98. Margaret Covino, Worcester,
Massachusetts, Court of Federal Claims
No: 23–1508V
99. Bartolomeo Marano, Boston,
Massachusetts, Court of Federal Claims
No: 23–1509V
100. Lynda Speer, Washington, District of
Columbia, Court of Federal Claims No:
23–1511V
[FR Doc. 2023–21498 Filed 9–28–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Notice of Request for Public
Comments on a Draft
Recommendation To Update the
HRSA-Supported Women’s Preventive
Services Guideline Relating to
Screening for Urinary Incontinence
Health Resources and Services
Administration (HRSA), U. S.
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
This notice seeks comments
on a draft recommendation to update
the HRSA-supported Women’s
Preventive Services Guidelines
(‘‘Guidelines’’) relating to Screening for
Urinary Incontinence. This draft
recommendation has been developed
through a cooperative agreement,
known as the Women’s Preventive
Services Initiative (WPSI), with the
American College of Obstetricians and
Gynecologists (ACOG), through which
they convene health professionals to
develop draft recommendations. Under
applicable law, non-grandfathered
group health plans and health insurance
issuers must include coverage, without
SUMMARY:
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
cost sharing, for certain preventive
services, including those provided for in
the HRSA-supported Guidelines. The
Departments of Labor, Health and
Human Services, and Treasury have
previously issued regulations, which
describe how group health plans and
health insurance issuers apply the
coverage requirements.
DATES: Members of the public are
invited to provide written comments no
later than October 30, 2023. All
comments received on or before this
date will be reviewed and considered by
WPSI and provided for further
consideration by HRSA in determining
the recommended update that it will
support.
ADDRESSES: Members of the public who
wish to provide comments can do so by
accessing the public comment web page
at https://www.womenspreventive
health.org/.
FOR FURTHER INFORMATION CONTACT:
Kimberly Sherman, HRSA, Maternal
and Child Health Bureau, telephone
(301) 443–8283, email: wellwomancare@
hrsa.gov.
SUPPLEMENTARY INFORMATION: Under
section 1001(5) of the Patient Protection
and Affordable Care Act, Public Law
111–148, which added section 2713 to
the Public Health Service Act, 42 U.S.C.
300gg-13, the preventive care and
screenings set forth in the Guidelines
are required to be covered without costsharing by certain group health plans
and health insurance issuers. HRSA
established the Guidelines in 2011
based on expert recommendations by
the Institute of Medicine, now known as
the National Academy of Medicine,
developed under a contract with the
Department of Health and Human
Services. Since 2011, there have been
advancements in science and gaps
identified in these guidelines, including
a greater emphasis on practice-based
clinical considerations. Since 2016,
HRSA has funded cooperative
agreements with ACOG for WPSI to
convene a coalition representing
clinicians, academics, and consumerfocused health professional
organizations to conduct a rigorous
review of current scientific evidence,
solicit and consider public input, and
make recommendations to HRSA
regarding updates to the Guidelines to
improve women’s health across the
lifespan. HRSA then determines
whether to support, in whole or in part,
the recommended updates to the
Guidelines. WPSI consists of an
Advisory Panel and two expert
committees, the Multidisciplinary
Steering Committee and the
Dissemination and Implementation
E:\FR\FM\29SEN1.SGM
29SEN1
Federal Register / Vol. 88, No. 188 / Friday, September 29, 2023 / Notices
Steering Committee, which are
comprised of a broad coalition of
organizational representatives who are
experts in disease prevention and
women’s health issues. With oversight
by the Advisory Panel, and with input
from the Multidisciplinary Steering
Committee, WPSI examines the
evidence to develop new (and update
existing) recommendations for women’s
preventive services. WPSI’s
Dissemination and Implementation
Steering Committee takes HRSAapproved recommendations and
disseminates them through the
development of implementation tools
and resources for both patients and
practitioners.
WPSI bases its recommended updates
to the Guidelines on review and
synthesis of existing clinical guidelines
and new scientific evidence, following
the National Academy of Medicine
standards for establishing foundations
for and rating strengths of
recommendations, articulation of
recommendations, and external reviews.
Additionally, HRSA requires that WPSI
incorporate processes to assure
opportunity for public comment,
including participation by patients and
consumers, in the development of its
recommendations to the updated
Guidelines.
removal, if accepted by HRSA, will not
substantively change the existing
guideline. Second, the final sentence of
the clinical recommendation
recommends changing the word
‘‘referring’’ to ‘‘facilitating’’ to reflect
that clinicians in practice, after
screening for urinary incontinence, may
decide to treat or manage urinary
incontinence as part of standard
primary care services or refer to
specialists if specialist care is needed.
Lastly, WPSI recommended minor edits
to the language of the Guideline for the
purposes of clarity. These minor edits
have no substantive effect on the
requirement for coverage without costsharing.
Members of the public can view the
complete updated draft
recommendation, which includes the
implementation considerations and
research recommendations, by accessing
the initiative’s web page at https://
www.womenspreventivehealth.org/.
Extramural Research, National Eye Institute,
National Institutes of Health, 6700 B
Rockledge Dr., Rockville, MD 20892, 301–
451–2020, hoshawb@mail.nih.gov.
Name of Committee: National Eye Institute
Special Emphasis Panel; Pathways to
Independence (K99) Applications.
Date: November 6, 2023.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, 6700B
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Ashley Fortress, Ph.D.,
Designated Federal Official, Division of
Extramural Activities, National Eye Institute,
National Institutes of Health, 6700 B
Rockledge Dr., Bethesda, MD 20817, (301)
451–2020, ashley.fortress@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.867, Vision Research,
National Institutes of Health, HHS)
Carole Johnson,
Administrator.
[FR Doc. 2023–21490 Filed 9–28–23; 8:45 am]
Dated: September 25, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
[FR Doc. 2023–21514 Filed 9–28–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
The Existing Guideline States
National Institutes of Health
National Institute of Nursing Research;
Notice of Meeting
‘‘Screening for Urinary Incontinence
WPSI recommends screening women
for urinary incontinence annually.
Screening should ideally assess whether
women experience urinary incontinence
and whether it impacts their activities
and quality of life. The Women’s
Preventive Services Initiative
recommends referring women for
further evaluation and treatment if
indicated.’’
National Eye Institute; Notice of Closed
Meetings
Draft Updated Clinical
Recommendation for Public Comment
‘‘Screening for Urinary Incontinence
The Women’s Preventive Services
Initiative recommends screening women
for urinary incontinence annually.
Screening should assess whether
women experience urinary incontinence
and whether it impacts their activities
and quality of life. If indicated,
facilitating further evaluation and
treatment is recommended.’’
lotter on DSK11XQN23PROD with NOTICES1
67319
Discussion of Draft Updated Clinical
Recommendation
WPSI recommended several minor
updates to the language of this
Guideline. First, the word ‘‘ideally’’ is
recommended to be removed from the
second sentence for brevity, and its
VerDate Sep<11>2014
21:46 Sep 28, 2023
Jkt 259001
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; Mentored Clinical
Scientist Research Career Development
Award (K08/K23) and Conference Grant
(R13) Applications.
Date: October 26, 2023.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, 6700
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Brian Hoshaw, Ph.D.,
Designated Federal Official, Division of
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Nursing Research.
This will be a hybrid meeting held inperson and virtually and will be open to
the public as indicated below.
Individuals who plan to attend inperson or view the virtual meeting and
need special assistance or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
can be accessed from the NIH Videocast
at the following link: https://
videocast.nih.gov/
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Nursing Research.
E:\FR\FM\29SEN1.SGM
29SEN1
]]>Agencies
[Federal Register Volume 88, Number 188 (Friday, September 29, 2023)]
[Notices]
[Pages 67318-67319]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21514]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Notice of Request for Public Comments on a Draft Recommendation
To Update the HRSA-Supported Women's Preventive Services Guideline
Relating to Screening for Urinary Incontinence
AGENCY: Health Resources and Services Administration (HRSA), U. S.
Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice seeks comments on a draft recommendation to update
the HRSA-supported Women's Preventive Services Guidelines
(``Guidelines'') relating to Screening for Urinary Incontinence. This
draft recommendation has been developed through a cooperative
agreement, known as the Women's Preventive Services Initiative (WPSI),
with the American College of Obstetricians and Gynecologists (ACOG),
through which they convene health professionals to develop draft
recommendations. Under applicable law, non-grandfathered group health
plans and health insurance issuers must include coverage, without cost
sharing, for certain preventive services, including those provided for
in the HRSA-supported Guidelines. The Departments of Labor, Health and
Human Services, and Treasury have previously issued regulations, which
describe how group health plans and health insurance issuers apply the
coverage requirements.
DATES: Members of the public are invited to provide written comments no
later than October 30, 2023. All comments received on or before this
date will be reviewed and considered by WPSI and provided for further
consideration by HRSA in determining the recommended update that it
will support.
ADDRESSES: Members of the public who wish to provide comments can do so
by accessing the public comment web page at https://www.womenspreventivehealth.org/.
FOR FURTHER INFORMATION CONTACT: Kimberly Sherman, HRSA, Maternal and
Child Health Bureau, telephone (301) 443-8283, email:
[email protected].
SUPPLEMENTARY INFORMATION: Under section 1001(5) of the Patient
Protection and Affordable Care Act, Public Law 111-148, which added
section 2713 to the Public Health Service Act, 42 U.S.C. 300gg-13, the
preventive care and screenings set forth in the Guidelines are required
to be covered without cost-sharing by certain group health plans and
health insurance issuers. HRSA established the Guidelines in 2011 based
on expert recommendations by the Institute of Medicine, now known as
the National Academy of Medicine, developed under a contract with the
Department of Health and Human Services. Since 2011, there have been
advancements in science and gaps identified in these guidelines,
including a greater emphasis on practice-based clinical considerations.
Since 2016, HRSA has funded cooperative agreements with ACOG for WPSI
to convene a coalition representing clinicians, academics, and
consumer-focused health professional organizations to conduct a
rigorous review of current scientific evidence, solicit and consider
public input, and make recommendations to HRSA regarding updates to the
Guidelines to improve women's health across the lifespan. HRSA then
determines whether to support, in whole or in part, the recommended
updates to the Guidelines. WPSI consists of an Advisory Panel and two
expert committees, the Multidisciplinary Steering Committee and the
Dissemination and Implementation
[[Page 67319]]
Steering Committee, which are comprised of a broad coalition of
organizational representatives who are experts in disease prevention
and women's health issues. With oversight by the Advisory Panel, and
with input from the Multidisciplinary Steering Committee, WPSI examines
the evidence to develop new (and update existing) recommendations for
women's preventive services. WPSI's Dissemination and Implementation
Steering Committee takes HRSA-approved recommendations and disseminates
them through the development of implementation tools and resources for
both patients and practitioners.
WPSI bases its recommended updates to the Guidelines on review and
synthesis of existing clinical guidelines and new scientific evidence,
following the National Academy of Medicine standards for establishing
foundations for and rating strengths of recommendations, articulation
of recommendations, and external reviews. Additionally, HRSA requires
that WPSI incorporate processes to assure opportunity for public
comment, including participation by patients and consumers, in the
development of its recommendations to the updated Guidelines.
The Existing Guideline States
``Screening for Urinary Incontinence
WPSI recommends screening women for urinary incontinence annually.
Screening should ideally assess whether women experience urinary
incontinence and whether it impacts their activities and quality of
life. The Women's Preventive Services Initiative recommends referring
women for further evaluation and treatment if indicated.''
Draft Updated Clinical Recommendation for Public Comment
``Screening for Urinary Incontinence
The Women's Preventive Services Initiative recommends screening
women for urinary incontinence annually. Screening should assess
whether women experience urinary incontinence and whether it impacts
their activities and quality of life. If indicated, facilitating
further evaluation and treatment is recommended.''
Discussion of Draft Updated Clinical Recommendation
WPSI recommended several minor updates to the language of this
Guideline. First, the word ``ideally'' is recommended to be removed
from the second sentence for brevity, and its removal, if accepted by
HRSA, will not substantively change the existing guideline. Second, the
final sentence of the clinical recommendation recommends changing the
word ``referring'' to ``facilitating'' to reflect that clinicians in
practice, after screening for urinary incontinence, may decide to treat
or manage urinary incontinence as part of standard primary care
services or refer to specialists if specialist care is needed. Lastly,
WPSI recommended minor edits to the language of the Guideline for the
purposes of clarity. These minor edits have no substantive effect on
the requirement for coverage without cost-sharing.
Members of the public can view the complete updated draft
recommendation, which includes the implementation considerations and
research recommendations, by accessing the initiative's web page at
https://www.womenspreventivehealth.org/.
Carole Johnson,
Administrator.
[FR Doc. 2023-21514 Filed 9-28-23; 8:45 am]
BILLING CODE 4165-15-P
